Review : Efek Samping Obat Antituberkulosis Oral Lini Pertama Pada Anak

Shintani Ayunda Khairunnisa, Irma Melyani Puspitasari

Abstrak


World Health Organization (WHO) melaporkan tingginya tingkat kematian pada anak (<15 tahun) akibat tuberkulosis pada tahun 2021. Tingginya kasus disebutkan karena akses yang buruk terhadap diagnosis dan pengobatan. Pengobatan tuberkulosis memerlukan penggunaan obat antituberkulosis (OAT) dalam jangka panjang, namun pembahasan tentang efek samping OAT tersebut terhadap anak jarang dibahas. Penulisan artikel review ini bertujuan untuk mengetahui efek samping OAT lini pertama pada anak untuk mencegah risiko efek samping serius hingga kematian pada anak akibat penggunaan OAT lini pertama. Artikel review ini disususn dari artikel, jurnal, atau laporan kasus terkait efek samping OAT lini pertama pada anak yang telah terbit pada situs Sciencedirect, Pubmed-NCBI, dan Google Scholar. Berdasarkan artikel yang ditinjau, didapatkan bahwa efek samping serius OAT lini pertama pada anak jarang terjadi, dengan efek samping yang paling banyak dilaporkan adalah hepatoksisitas. Walaupun kejadian efek samping pada anak jarang dilaporkan, tenaga kesehatan tetap harus waspada terhadap kemungkinan efek samping tersebut melalui follow up rutin pasien.

Teks Lengkap:

PDF

Referensi


Arnold, C., Ericson, J., Kohman, J., Corey, K., Oh, M., Onabanjo, J., Hornik, C., Clark, R., Benjamin, D., Smith, P., Chu, V., & on behalf of the Best Pharmaceuticals for Children Act–Pediatric Trials Network Administrative Core Committee. (2015). Rifampin Use and Safety in Hospitalized Infants. American Journal of Perinatology, 32(06), 565–570. https://doi.org/10.1055/s-0034-1543955

Atkinson, A., & Kitai, I. (2014). Rifampin Hypersensitivity in a 2-year-old Child With Successful Rapid Oral Desensitization. The Pediatric Infectious Disease Journal, 33(7). https://doi.org/10.1097/INF.0000000000000295

Barrosa Maia, E., Reis Silva, T., Neves, N., Félix, M., & Chaves Loureiro, C. (2014). P25 ‐ Hypersensitivity/adverse reactions to antituberculosis drugs – a case report. Clinical and Translational Allergy, 4(S1). https://doi.org/10.1186/2045-7022-4-S1-P80

Baytunca, M. B., Erermis, S., Bildik, T., & Kayahan, B. (2015). Isoniazid-Induced Psychosis with Obsessive-Compulsive Symptoms (Schizo-Obsessive Disorder) in a Female Child. Journal of Child and Adolescent Psychopharmacology, 25(10), 819–820. https://doi.org/10.1089/cap.2014.0065

Carvalho, E., Rossoni, A., Tahan, T., Rossoni, M., & Rodrigues, C. (2018). Treatment Regimens For Tuberculosis In Children And Related Adverse Effects. Residência Pediátrica, 8(1), 20–26. https://doi.org/10.25060/residpediatr-2018.v8n1-03

Chang, S.-H., Nahid, P., & Eitzman, S. R. (2014). Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection. Journal of the Pediatric Infectious Diseases Society, 3(3), 221–227. https://doi.org/10.1093/jpids/pit089

Cruz, A. T., Ahmed, A., Mandalakas, A. M., & Starke, J. R. (2013). Treatment of Latent Tuberculosis Infection in Children. Journal of the Pediatric Infectious Diseases Society, 2(3), 248–258. https://doi.org/10.1093/jpids/pit030

Eyuboglu, T. Ş., Durmus, S. Y., Karamert, S. S., Kaman, A., Teke, T., Oz, F. N., & Tanır, G. (2019). Reversible Color Blindness due to Ethambutol in a Pediatric Patient with Pulmonary Tuberculosis. European Respiratory Journal, 54(PA1063). https://doi.org/10.1183/13993003.congress-2019.PA1063

Faiz, S. N., Haque, M., & Hoque, S. M. K. (2020). Antitubercular Drug-Induced Hepatotoxicity: A Comprehensive Review. Journal of Army Medical College Chattogram, 3(1), 33–37.

Garcia-Prats, A. J., Svensson, E. M., Winckler, J., Draper, H. R., Fairlie, L., van der Laan, L. E., Masenya, M., Schaaf, H. S., Wiesner, L., Norman, J., Aarnoutse, R. E., Karlsson, M. O., Denti, P., & Hesseling, A. C. (2021). Pharmacokinetics and safety of high-dose rifampicin in children with TB: The Opti-Rif trial. Journal of Antimicrobial Chemotherapy, 76(12), 3237–3246. https://doi.org/10.1093/jac/dkab336

Kemenkes RI. (2016). Petunjuk Teknis Manajemen dan Tatalaksana TB Anak. Kementerian Kesehatan RI.

Levy, M., Rigaudière, F., de Lauzanne, A., Koehl, B., Melki, I., Lorrot, M., & Faye, A. (2015). Ethambutol-related Impaired Visual Function in Childrens Less than 5 Years of Age Treated for a Mycobacterial Infection: Diagnosis and Evolution. Pediatric Infectious Disease Journal, 34(4), 346–350. https://doi.org/10.1097/INF.0000000000000589

Li, Y., Zhu, Y., Zhong, Q., Zhang, X., Shu, M., & Wan, C. (2017). Serious Adverse Reactions From Anti-tuberculosis Drugs Among 599 Children Hospitalized for Tuberculosis. Pediatric Infectious Disease Journal, 36(8), 720–725. https://doi.org/10.1097/INF.0000000000001532

Qu, C., Li, X., Zheng, Z., & Zhu, J. (2015). Successful diagnosis of hyperpyrexia induced by isoniazid in a child with suspected extra-pulmonary tuberculosis. Int J Clin Exp Med, 8(5), 8249–8253.

Sadanshiv, M., George, A. A., Mishra, A. K., & Kuriakose, C. K. (2018). Rifampicin-induced immune allergic reaction. Tropical Doctor, 48(2), 156–159. https://doi.org/10.1177/0049475517724689

Science, M., Ito, S., & Kitai, I. (2013). Isoniazid toxicity in a 5-year-old boy. Canadian Medical Association Journal, 185(10), 894–896. https://doi.org/10.1503/cmaj.121732

Shah, I., Jadhao, N., Mali, N., Deshpande, S., Gogtay, N., & Thatte, U. (2019). Pharmacokinetics of isoniazid in Indian children with tuberculosis on daily treatment. The International Journal of Tuberculosis and Lung Disease, 23(1), 52–57. https://doi.org/10.5588/ijtld.18.0463

Sharawat, I. K., & Dawman, L. (2021). Toddler With Intermittent Abnormal Behavior: Is It Isoniazid-Induced Psychosis? Pediatric Emergency Care, 37(1), e60–e61. https://doi.org/10.1097/PEC.0000000000001555

Shetty, N. S., & Shah, I. (2019). Isoniazid-induced neuropathy in a pre-pubertal child. Paediatrics and International Child Health, 39(3), 216–218. https://doi.org/10.1080/20469047.2018.1482996

Şişmanlar, T., Aslan, A. T., & Budakoğlu, I. (2015). Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide? Journal of Tropical Pediatrics, 61(5), 351–356. https://doi.org/10.1093/tropej/fmv042

Torres-Fernandez, D., de Pazos Azpeitia, B., Gijon Mediavilla, M., Lopez-Roa, P., Epalza, C., Grasa Lozano, C. D., & Blazquez-Gamero, D. (2020). Severe Rifampicin-induced Vitamin K Deficiency Coagulopathy in a Child. Pediatric Infectious Disease Journal, 39(9), 833–834. https://doi.org/10.1097/INF.0000000000002728

World Health Organization. (2014). Guidance for national tuberculosis programmes on the management of tuberculosis in children (2nd ed). World Health Organization. https://apps.who.int/iris/handle/10665/112360

World Health Organization. (2022). Global Tuberculosis Report 2022. World Health Organization.




DOI: https://doi.org/10.24198/farmaka.v21i2.46054

DOI (PDF): https://doi.org/10.24198/farmaka.v21i2.46054.g20648

Refbacks

  • Saat ini tidak ada refbacks.




Sitasi manajer:   

 

 

Jurnal ini diindeks dalam:

 

 

View My Stats 

ISSN: 1693-1424

e-ISSN: 2716-3075

 

Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Copyright © 2013 Jurnal Farmaka - All Right Reserved